RegCell, a startup founded by Shifumi Sakaguchi, a distinguished professor at Osaka University in Japan who has been nominated for the Nobel Prize in Physiology or Medicine, and others, is expected to launch its first clinical trial in the United States as early as 2026. The target is autoimmune diseases where the immune system attacks the body’s own cells, and the company aims to develop therapeutic drugs using “regulatory T cells” discovered by Sakaguchi.
